Skip to search boxSkip to navigationSkip to main content

miR-23b represses proto-oncogene Src kinase and functions as methylation-silenced tumor suppressor with diagnostic and prognostic significance in prostate cancer

  • Shahana Majid
    ,
  • Altaf A. Dar
    ,
  • ,
  • Sumit Arora
    ,
  • Varahram Shahryari
    ,
  • Mohd Saif Zaman
*Corresponding author for this work
  • VA Medical Center
    ,
  • California Pacific Medical Center
Scholary Output:
Contribution to journal
Article
Research
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

<p>The miRNAs have great potential as biomarkers and therapeutic agents owing to their ability to control multiple genes and potential to influence cellular behavior. Here, we identified that miR-23b is a methylation-silenced tumor suppressor in prostate cancer. We showed that miR-23b expression is controlled by promoter methylation and has great promise as a diagnostic and prognostic biomarker in prostate cancer. High levels of miR-23b expression are positively correlated with higher overall and recurrence-free survival in patients with prostate cancer. Furthermore, we elucidated the tumor suppressor role of miR-23b using in vitro and in vivo models. We showed that proto-oncogene Src kinase and Akt are direct targets of miR-23b. Increased expression of miR-23b inhibited proliferation, colony formation, migration/invasion, and triggered G0-G1 cell-cycle arrest and apoptosis in prostate cancer. Overexpression of miR-23b inhibited epithelial-to-mesenchymal transition (EMT) causing a decline in mesenchymal markers Vimentin and Snail and increasing the epithelial marker, E-cadherin. Depletion of Src by RNA interference conferred similar functional effects as that of miR-23b reconstitution. miR-23b expression caused a dramatic decrease in tumor growth in nude mice and attenuated Src expression in excised tumors compared with a control miR. These findings suggest that miR-23b is a methylation-silenced tumor suppressor that may be a useful biomarker in prostate cancer. Loss of miR-23b may confer proliferative advantage and promote prostate cancer migration and invasion, and reexpression of miR-23b may contribute to the epigenetic therapy for prostate cancer.</p>

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Research
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 6435-6446 (12 pages)

Journal (Volume, Issue Number)

Cancer Research (Volume 72, Issue 24)

Publication milestones

  • Published - 12/15/2012

Publication status

Published - 12/15/2012

ISSN

0008-5472

Publication IDs

  • Scopus: 84871222985
  • PubMed: 23074286

Publication metrics

Metrics

Scopus
citations
SciVal
citations
123
Fractional count
1
Fractional count
0.09
Fractional count
10
Fractional count
0.91
Fractional count
1
Fractional count
1
SciVal
FWCI
3.48
SciVal
Author count
11
SciVal
Paper percentile
98
SciVal
Top percentile
5

PlumX, opens in new tab

Captures
46
Citation count
149

Funding Details

FunderFunding number
NIDDK
T32DK007790